Low dose continuous IV etomidate for severe Cushing’s syndrome in the non-critical care setting: a clinical study
(2019) Belgian Endocrine Society 2019 — Location: (Belgium) Bruxelles (18.October.2019)
Files
2019_Constantinescu_BES_007.pdf
Open Access - Adobe PDF
- 255.99 KB
Details
- Authors
- Abstract
- Introduction: Severe Cushing’s syndrome (CS) is defined by extremely high serum cortisol levels (usually >1000 nM), along with severe and deadly complications, including sepsis, heart failure, acute psychosis, vascular thrombosis, digestive haemorrhage and bowel perforation. Rapid control of such hypercortisolism is mandatory and has been shown to decrease operative mortality and complications. Oral treatments such as ketoconazole and metyrapone are often inadequate in the face of life threatening complications and limited oral intake possibilities. Etomidate is a hypnotic agent widely used in general anaesthesia induction, while also being one of the most potent inhibitors of 11-B-hydroxylase and therefore of cortisol secretioni. Low dose continuous intravenous (IV) infusion of etomidate has been shown to rapidly decrease cortisol levels in patients with severe CS in the ICU settingiiiii, without causing harmful side effects (myoclonus or adrenal crisis) A safe use of etomidate has been also suggested for similar indication in the non-ICU settingiv. [...]
- Affiliations
Citations
Constantinescu, S. M., Lefebvre, A., Furnica, R.-M., & Maiter, D. (2019). Low dose continuous IV etomidate for severe Cushing’s syndrome in the non-critical care setting: a clinical study. Endocrine Abstracts, 64, 7. https://hdl.handle.net/2078.5/31196 (Original work published 2019)